Objective We aimed to analyze trends in drug-eluting stents (DES) use in four international health care and regulatory settings.
Drug-eluting stents (DES) are proven to reduce restenosis in selected populations compared with bare metal stents (BMS).
1-4 Consequently, they were licensed for use across Europe and North America. Despite their established effectiveness in randomized controlled trials, the clinical and cost effectiveness of unrestricted DES use in routine practice has since been debated. [5] [6] [7] [8] Given the financial consequences of widespread use of these more expensive stents, some health care systems introduced guidelines or encouraged restricted indications for DES use; such approaches have varied. [9] [10] [11] [12] Against this background, abstracts presented at the World Congress of Cardiology (WCC) in September 2006 brought into question the safety of DES and, in particular, the complication of late stent thrombosis. [13] [14] [15] [16] [17] Anecdotal accounts suggest a differential approach to DES use internationally and reductions in use following the issue of late stent thrombosis. Previous studies have examined the uptake of DES within single health care systems or analyzed the impact of DES on patient selection for percutaneous coronary intervention (PCI) versus coronary artery bypass grafting. [18] [19] [20] However, there are limited patient-level analyses of international practice. This study aimed to show whether the adoption and use of DES varied internationally, and how the stent thrombosis controversy has affected practice.
Methods

Data sources and patient populations
This study involved collaboration between centers from four countries that have established large regional or national PCI data sets of consecutive patients treated in routine clinical practice. The data sets included were the APPROACH Registry (Alberta, Canada), BWGIC Registry, Mayo Clinic PCI Registry (Rochester, MN), and the Scottish Coronary Revascularisation Registry (Scotland, UK) ( Table I) . In each registry, data collection and entry is prospective and performed by a combination of administrative and clinical staff. All data were stripped of unique patient identifiers. 
Variables and definitions
Data fields obtained included patient-level demographic details, diabetic status, indication for PCI, and lesion-level angiographic details including type of intervention, type of stent, treated vessel, and stent dimensions. Diabetes mellitus was defined as either type 1 or type 2 diabetes mellitus treated with insulin or oral hypoglycemic agents. Clinical presentation was recorded as the principal indication for PCI. Stent diameter was the maximum diameter stent successfully deployed within each lesion, and lesion length was the total length stented.
Statistical analysis
The unit of analysis was the lesion. We defined the binary outcome for each lesion as treatment with either DES or BMS. Patients who did not receive a stent were excluded from the analysis. Case mix at baseline was summarized for each registry. Patient and lesion level variables are presented in relation to their respective denominators. Variables are reported as number (percentage) for categorical data, mean (SD) for normally distributed data, and median (interquartile range) for skewed data. Data were compared between countries using one-way analysis of variance (normal distribution), Kruskall-Wallis test (skewed or ordinal data) or χ 2 test (categorical data). 22 and the adjusted model constructed using the "mgcv" package (v1. , with the nonlinear time trend modeled using cubic splines. No extramural funding was used to support this work. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents
Results
Baseline characteristics
All consecutive lesions treated with a stent during the study period were included in the overall analysis. In total, 178,504 stented lesions in the four geographical areas were included in the overall comparison. For the analyses by diabetic and clinical indication subgroup, 118,827 lesions were included from the four registries. For analyses by lesion dimension and the adjusted model, 68,781 lesions were included from the APPROACH, Mayo Clinic, and Scottish registries. Procedural volume during the study was constant within the APPROACH, Mayo Clinic, and BWGIC Registries but was seen to increase year-on-year in the Scottish Registry. Case mix for each registry period is described in Table II . Statistical differences between registries were identified for clinical and demographic case mix variables.
Adoption and peak use of drug-eluting stents
The Mayo Clinic PCI Registry demonstrated rapid adoption of DES into clinical practice (Figures 1-5 ). Peak use was observed by February 2005 when 91% of stented lesions were treated with a DES. Peak use of N89% 
Patient selection for drug-eluting stents
In Alberta and Scotland, selection for DES on patient and lesion characteristics was evident throughout. At peak adoption, high levels of DES use in lesions at highest baseline risk of restenosis (b3/≥18 mm) was observed: 75% in Alberta, 87% in Scotland and 98% at the Mayo Clinic (Figure 2, D) . However, variation between registries was greater in lesions at moderate risk of restenosis (N3/≥18, ≤3/b18 mm [ Figure 2 , B and C]) and further still for lesions at lowest baseline risk (N3/b18 mm [ Figure 2 , A]) due to lower use in Alberta and Scotland among these subgroups. In Alberta and Scotland, relatively higher DES use by subgroup was also observed for diabetic patients (Figure 3 ). In contrast, lower DES use was observed for STEMI ( Figure 4 ) in Scotland and Alberta, but not the Mayo Clinic.
Where Belgian subgroup data were available, they demonstrated marked differences in use by diabetic status. DES use among people with diabetes showed no statistical difference to the Mayo Clinic registry in late 2006 and was higher than both the Scottish and Canadian registries ( Figure 3 ). In common with the Scottish and Canadian registries, relatively lower DES use was observed for STEMI ( Figure 4 ).
Reductions in drug-eluting stent use
The Mayo Clinic PCI Registry recorded small reductions in DES use during 2005, followed by a steeper decline during 2006. From the unadjusted smoothed trend line, the estimated absolute reduction from peak DES use was 16%, a relative reduction of 18%. In comparison with the other registries, DES use remained statistically higher throughout maintained N74% of stented lesions (Figures 1 and 5) . Differential reductions in DES use by clinical indication were observed in the US registry. Reductions in DES use were greater in patients treated for STEMI (Figure 4) , and N3/b18-mm lesions (Figure 2) .
In both Alberta and Scotland, DES use started to decline in the second quarter of 2006 (Figures 1 and 5) . For Alberta, a 19% absolute reduction and 34% relative reduction from peak DES use was observed by the end of the study period. In Scotland, a smaller absolute reduction of 16%, a relative reduction of 28%, was observed. In both registries, pre-evident patient selection remained apparent. In contrast, the BWGIC Registry showed a 1% absolute and 3% relative reduction in DES use during 2006 (Figure 1) . By the end of the study period, DES were used in 75% of stented lesions in the Mayo Clinic, 42% in Scotland, 37% in Alberta and 32% in Belgium (Figure 1) .
Discussion
This study of PCI practice in four countries demonstrated wide variations in the adoption and utilization of DES. We also established that DES use reduced in all registries during 2006 and 2007; the timing and extent of these reductions varied by registry. Marked differences in use by clinical subgroup were evident throughout and observations held even after adjustment for case mix differences.
Adoption and peak use
Variations in adoption and peak use exist despite the international nature of clinical scientific evidence and the widespread marketing and availability of DES. In the Mayo Clinic Registry, increased DES use corresponded closely with the Food and Drug Administration approval of the sirolimus-eluting Cypher stent 23 Drug-eluting stent use varies at hospital level within single health care systems. [18] [19] [20] Influences are thought to include differences in funding (eg, private/government, proportion of patients insured), type of hospital (eg, academic/non academic, urban/rural), and local priority setting. Individual interventional cardiologists also vary in their use of DES, and their rate of technology adoption. 19, 25 Furthermore, it is possible that, in the United States in particular, adoption may have been partly driven by concerns of medical malpractice with underuse. 26 However, such disparities in international adoption patterns seem unlikely to be fully explained by individual clinician preference, local hospital factors, differing patient selection for PCI over other treatments (such as coronary artery bypass grafting or medical therapy), or unaccounted for clinical factors.
Indeed, the adoption of high cost new technologies are thought to be sensitive to the stringency of regulation, the responsiveness of payment systems to changes in practice (eg, centrally funded, reimbursement, private), the autonomy of local decision making, and overall levels of health care funding. 27 In this study, we showed rapid uptake of DES at the Mayo Clinic-a private, not-forprofit, academic institution within the influence of the US health care system, where stent choice was at the discretion of individual operators. As an example here, there is low regulation, a payment system rapidly responsive to changes in practice, high local autonomy, Crude DES use by registry (smooth estimate with 95% CI).
and high levels of health care funding. Such an environment encourages rapid and high levels of technology adoption as seen with DES in this study.
As a further illustration, early policy in Belgium was to only reimburse the full cost of DES to hospitals for use in diabetic patients. 12 The influence of this policy on practice is clearly demonstrated in this study. In this case, regulation and payment were strictly controlled, local autonomy was therefore low, and overall costs were controlled; the result was slow adoption and low peak use. A recent health technology assessment in Belgium has concluded against the extension of DES use in other clinical indications on cost grounds. 12 
Differential selection for drug-eluting stents
We demonstrated differential selection for DES in Scotland and Alberta based on patient and lesion characteristics. In the United Kingdom and Canada, early cost-effectiveness analyses and health technology assessments resulted in clinical policies that favored the "targeting" of DES to patients felt to be at higher risk of restenosis. 6, 9, 11, [28] [29] [30] In both the United Kingdom and Canada, these recommendations explicitly considered cost and were designed to limit overall use. In the United Kingdom, The National Institute for Health and Clinical Excellence recommended DES in non-myocardial infarction patients with lesions N15 mm length and in vessels b3 mm. 9, 10 Using similar rationale, the Canadian province of Ontario recommended DES use in diabetic patients, lesions N18 mm, vessels of ≤2.75 mm, or an otherwise defined high risk lesion.
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Both UK and Canadian health care systems are largely publicly funded, although neither employs a system of direct reimbursement for DES used in recommended indications. In such health care systems, the interventional cardiologist plays a role in "gate-keeping" to ensure overall costs are limited and DES are used for those considered to have the greatest clinical "need." Our data demonstrate that such policy has influenced clinical practice during the period of study. Drug-eluting stent use by registry for lesion dimensions: ≥3/b18 (A), ≥3/≥18 (B), b3/b18 (C), and b3/≥18 mm (D) (smooth estimate with 95% CI).
Reductions in drug-eluting stent use
Several studies, initially presented at the WCC conference in September 2006, questioned the safety of DES linked to the risk of late stent thrombosis. [13] [14] [15] [16] [17] Subsequent published meta-analyses and large observational studies have since shown safety and efficacy of DES without major safety concerns. [31] [32] [33] [34] [35] [36] This evidence is particularly strong for "on-label" patients studied in the pivotal randomized controlled trials, although further studies have included other important subgroups. [37] [38] [39] [40] Thus, the "turn point" for reductions in DES use is perhaps surprising. A possible explanation is that physicians were beginning to manage individual cases of late stent thrombosis in clinical practice; a complication described as far back as 2004. 41, 42 Increasing caution in the use of DES, before the adverse publicity in September 2006, may have resulted.
By 2007, evidence of selection of patients for DES was evident within the US-based registry, in particular, reduced use among patients treated for STEMI. In the Canadian and UK-based registries, pre-evident factors effecting selection remained, and in common with the Mayo Clinic Registry, reductions in patients treated for STEMI were particularly marked. A possible explanation lies in the importance of dual antiplatelet therapy in preventing thrombotic events 43, 44 ; an assessment of future patient compliance is particularly challenging within the acute setting and may discourage the use of DES.
Implications and determinants of use
The optimum strategy for adoption and use for DES is not clear. Were DES adopted too early, particularly within United States, before a full evaluation of the device in many clinical scenarios? Targeted DES use, for example, in the United Kingdom and Canada, may make economic sense. However, "off-label" use was encouraged (eg, very Drug-eluting stent use by registry for diabetics (smooth estimate with 95% CI).
Figure 4
Drug-eluting stent use by registry for STEMI (smooth estimate with 95% CI).
Figure 5
Adjusted DES use by registry (smooth estimate with 95% CI).
long lesions), and many patients for whom benefit and safety was established were excluded from guidance. Furthermore, equity of use in systems where the interventional cardiologist acts as "gatekeeper" can be compromised. 19 Finally, a strict reimbursement system, such as in Belgium, appears affective in controlling uptake, limiting overall use and is probably more equitable. However, this system may be less flexible to change with the emergence of new data.
Clinically efficacious but expensive new technologies are frequently developed for use in clinical practice. Drug-eluting stents are a classic case in point. We have shown wide international differences in the approach to DES and varying reductions in use following reports of late stent thrombosis. These findings raise generic questions with respect to the determinants of utilization which include clinical evidence and its applicability to actual practice; public and medical perception, including the importance of marketing and (adverse) publicity; the role of national regulatory and rationing agencies; and the influence and extent of health service control.
Strengths and weaknesses of the study
Our study has provided an overview of international PCI practice since the introduction of DES. While international differences in DES use and recent reductions are often alluded to, no study to date has outlined this in detail. The comparison of a sample of North American and European practice is therefore unique in the current literature. Other strengths include the comprehensive case ascertainment and collection of procedural covariates key to clinical decision-making. Data collected by the registries are broadly consistent and the majority of relevant clinical details can be reliably determined. We believe that observations and discussion of practice influences are germane beyond the areas studied.
Our study has some weaknesses. The Mayo Clinic as a major academic centre may not necessarily directly reflect US practice and includes patients from outside the local region. As a relatively smaller community of operators, practice may also change at a more rapid rate. In addition, a small fraction of total US practice is represented, with comparatively greater proportions of UK, Canadian (both approximately 10%), and Belgian (close to 100%) clinical activity represented. We accept that this is therefore not a comprehensive survey; sample proportions from each country vary and that other practice patterns are possible, even within the countries studied.
We used registry data to obtain a representation of actual clinical practice and rely on surrogates such as stent dimensions. Furthermore, each data set is not centrally audited, thus we cannot exclude idiosyncrasies between data sets. Despite this, key variables were defined consistently, and determined from original lesion and patient records.
Our study has an observational, descriptive design. To place our findings in context, we drew on previous literature and identified key external pressures on clinical practice. Because of this and the complex nature of the trends identified, much of our results and discussion are therefore qualitative. As with all observational studies, we cannot be sure that all relevant variables are accounted for within the adjusted analysis and it is not possible to demonstrate causal link between a given event and change in practice. Segmented timeseries analysis can be used in ecological studies to identify temporal changes in relation to external events; however, this approach would have been too simplistic in this case.
Conclusion
International adoption and use of DES showed wide variation in this study of PCI practice in four countries. Reductions in DES use were observed during 2006, but the timing and nature of this reduction also varied geographically. A consensus therefore does not exist for the optimum application of DES in clinical practice, although influences on stent choice in the "real world" are multifactorial. These data are a reminder of the gap that often exists between the goal of evidence-base medicine and actual clinical practice.
